BioNTech SE Sponsored ADR (NASDAQ:BNTX) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) have earned an average recommendation of “Moderate Buy” from the nineteen research firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation, twelve have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $125.69.

BNTX has been the topic of a number of research analyst reports. Wall Street Zen lowered shares of BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Berenberg Bank set a $140.00 price objective on BioNTech in a report on Wednesday, September 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNTech in a research note on Friday, October 2nd. UBS Group restated a “buy” rating on shares of BioNTech in a research report on Wednesday, September 16th. Finally, BMO Capital Markets downgraded shares of BioNTech from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $128.00 to $105.00 in a report on Tuesday, September 8th.

BioNTech Stock Down 0.5%

BNTX opened at $95.25 on Friday. BioNTech has a 12 month low of $79.52 and a 12 month high of $124.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. The stock has a market cap of $24.09 billion, a P/E ratio of -12.16 and a beta of 1.25. The stock’s 50 day moving average price is $99.06 and its 200 day moving average price is $95.14.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The business had revenue of $122.31 million for the quarter, compared to analyst estimates of $180.18 million. During the same period last year, the business posted ($1.60) earnings per share. BioNTech’s revenue for the quarter was down 59.5% on a year-over-year basis. As a group, research analysts predict that BioNTech will post -6.37 earnings per share for the current year.

Insider Activity

In other news, CEO Ugur Sahin sold 72,000 shares of the business’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $97.23, for a total transaction of $7,000,560.00. Following the sale, the chief executive officer directly owned 108,209 shares of the company’s stock, valued at $10,521,161.07. The trade was a 39.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 744,000 shares of company stock valued at $73,301,215. Insiders own 19.20% of the company’s stock.

Institutional Trading of BioNTech

A number of hedge funds have recently bought and sold shares of BNTX. Integrated Wealth Concepts LLC purchased a new stake in shares of BioNTech in the second quarter valued at $39,000. Caitong International Asset Management Co. Ltd grew its holdings in shares of BioNTech by 1,012.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company’s stock valued at $53,000 after buying an additional 506 shares in the last quarter. Vestcor Inc purchased a new position in shares of BioNTech during the fourth quarter valued at $153,000. Rockefeller Capital Management L.P. raised its position in BioNTech by 328.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company’s stock valued at $177,000 after buying an additional 1,423 shares during the period. Finally, Quantum Portfolio Management LLC purchased a new stake in BioNTech in the 1st quarter worth about $203,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.